InterVenn Biosciences operates at the intersection of biotechnology and advanced computation. The company's core work is in glycoproteomics - the analysis of sugar modifications on proteins - to develop new tools for clinical diagnostics, with a particular focus on oncology.
The firm has built a glycoproteomic analysis platform designed to process samples from a simple blood draw. This system transforms complex biological data into actionable clinical classifiers. The technology stack underpinning this platform draws heavily on machine learning, artificial intelligence, deep learning, and generative AI, including the use of foundation models.
Technical roles at InterVenn involve applying these AI disciplines to large-scale biological datasets. Engineers and scientists work to build and refine the models that interpret glycoproteomic patterns, a field where computational and biological expertise must converge.
